循环肿瘤DNA在消化系统肿瘤中的应用

doi:10.3969/j.issn.1006-7795.2023.06.015

摘要/Abstract

摘要： 循环肿瘤DNA（circulating tumor DNA，ctDNA)属于血浆游离DNA（circulating free DNA，cfDNA)的一种，是通过凋亡或坏死的肿瘤细胞释放到血液中，或由肿瘤直接分泌。ctDNA携带肿瘤特异性基因特征和表观遗传学特征，包括基因突变、染色体重排、拷贝数变异和甲基化改变。ctDNA属于液体活检技术，具有操作方便、重复性高、创伤性小等优势。ctDNA可应用于消化系统肿瘤早期癌症的筛查和诊断、指导治疗、监测治疗效果、分析术后残余病灶及预防疾病复发。本文对ctDNA的生物学特性、检测方法、在消化系统肿瘤中的应用进行了探讨。

关键词: 循环肿瘤DNA, 血浆游离DNA, 液体活检, 消化系统肿瘤

Abstract: Circulating tumor DNA (ctDNA) is a type of circulating free DNA (cfDNA), which is released into the blood by apoptotic or necrotic tumor cells, or directly secreted by tumors. ctDNA carries tumor-specific genetic and epigenetic characteristics, including gene mutations, chromosome rearrangements, copy number variations, and methylation changes. ctDNA liquid biopsy technique has the advantages of easy operation, high repeatability and minimal invasion. ctDNA can be used to screen and diagnose early stage of digestive system tumor, guide treatment, monitor therapeutic effect, analyze postoperative residual lesions and prevent disease recurrence. This article discusses the biological characteristics, detection methods, and application of ctDNA in digestive system neoplasms.

Key words: circulating tumor DNA, circulating free DNA, liquid biopsy, digestive system neoplasms

中图分类号:

于明鑫, 杨爱明. 循环肿瘤DNA在消化系统肿瘤中的应用[J]. 首都医科大学学报, 2023, 44(6): 999-1005.

Yu Mingxin, Yang Aiming. Application of circulating tumor DNA in digestive system neoplasms[J]. Journal of Capital Medical University, 2023, 44(6): 999-1005.

参考文献

［1］王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状［J］. 检验医学, 2022, 37(9): 877-881.
［2］张音洁, 王晰程. 循环肿瘤DNA在消化系统肿瘤中的临床应用［J］. 癌症进展, 2019, 17(2): 131-136.
［3］Mandel P, Metais P. Nuclear acids in human blood plasma［J］. C R Seances Soc Biol Fil, 1948, 142(3/4): 241-243.
［4］Caldas C, Hahn S A, Hruban R H, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia［J］. Cancer Res, 1994, 54(13): 3568-3573.
［5］Pessoa L S, Heringer M, Ferrer V P. ctDNA as a cancer biomarker: a broad overview［J］. Crit Rev Oncol Hematol, 2020, 155: 103109.
［6］蒋婷, 王平, 黄新恩. 液体活检在胃癌诊疗中的研究进展［J］. 医学研究杂志, 2022, 51(5): 22-25.
［7］许晶, 金顺花. 循环肿瘤DNA在消化系统肿瘤中的应用进展［J］. 医学研究生学报, 2022, 35(8): 883-888.
［8］Cui S H, Ye L, Wang H M, et al. Use of SuperARMS EGFR mutation detection kit to detect EGFR in plasma cell-free DNA of patients with lung adenocarcinoma［J］. Clin Lung Cancer, 2018, 19(3): e313-e322.
［9］Franczak C, Filhine-Tresarrieu P, Gilson P, et al. Technical considerations for circulating tumor DNA detection in oncology［J］. Expert Rev Mol Diagn, 2019, 19(2): 121-135.
［10］Postel M, Roosen A, Laurent-Puig P, et al. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective［J］. Expert Rev Mol Diagn, 2018, 18(1): 7-17.
［11］Liu K, Cui Y L, Li H, et al. The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique［J］. Crit Rev Oncol Hematol, 2023, 188: 104057.
［12］Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications［J］. J Hematol Oncol, 2022, 15(1): 131.
［13］Wardenaar R, Liu H Y, Colot V, et al. Evaluation of MeDIP-chip in the context of whole-genome bisulfite sequencing (WGBS-seq) in Arabidopsis［J］. Methods Mol Biol, 2013, 1067: 203-224.
［14］Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing［J］. Proc Natl Acad Sci U S A, 2011, 108(23): 9530-9535.
［15］Li H Z, Jing C W, Wu J Z, et al. Circulating tumor DNA detection: a potential tool for colorectal cancer management［J］. Oncol Lett, 2019, 17(2): 1409-1416.
［16］Newman A M, Bratman S V, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage［J］. Nat Med, 2014, 20(5): 548-554.
［17］Pinheiro M, Peixoto A, Rocha P, et al. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR［J］. Int J Colorectal Dis, 2022, 37(4): 895-905.
［18］Adashek J J, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening［J］. Cancers (Basel), 2021, 13(14): 3600.
［19］Food and Drug Administration (FDA). Nucleic acid based tests［EB/OL］. (2023-05-26)［2023-06-28］. https://www.fda.gov/medical-devices/in-vitro-diagnostics/nucleic-acid-based-tests.
［20］国家药品监督管理局. 数据查询［DB/OL］. ［2023-06-28］. https://www.nmpa.gov.cn/datasearch/home-index.html?itemId=ff8080817c8312c4017c9bbfc8de 0360&3jfdxVGGVXFo=1698930093503category=ylqx.
［21］Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening［J］. Clin Chem, 2008, 54(2): 414-423.
［22］Iyer P, Zekri A R, Hung C W, et al. Concordance of DNA methylation pattern inplasma and tumor DNA of Egyptian hepatocellular carcinoma patients［J］. Exp Mol Pathol, 2010, 88(1): 107-111.
［23］Gao J, Wang H X, Zang W C, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer［J］. Cancer Sci, 2017, 108(9): 1881-1887.
［24］Clifton K, Rich T A, Parseghian C, et al. Identification of actionable fusions as an anti-EGFR resistance mechanism using a circulating tumor DNA assay［J］. JCO Precis Oncol, 2019, 3:1-15.
［25］Martini G, Ciardiello D, Famiglietti V, et al. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: individual patient data pooled analysis of CRICKET and CAVE trials［J］. Cancer Med, 2023, 12(8): 9392-9400.
［26］Chennamadhavuni A, Kasi P M. Circulating tumor DNA in identifying resistant sub-clones post EGFR blockade: implications for EGFR rechallenge［J］. Front Oncol, 2022, 12: 847299.
［27］Montagut C, Argilés G, Ciardiello F, et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial［J］. JAMA Oncol, 2018, 4(4): e175245.
［28］Dasari A, Morris V K, Allegra C J, et al. ctDNA applications and integration in colorectal cancer: an NCI colon and rectal-anal task forces whitepaper［J］. Nat Rev Clin Oncol, 2020, 17(12): 757-770.
［29］Kim S, Sun J H, Kim H, et al. Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: a case report［J］. World J Clin Cases, 2023, 11(1): 218-224.
［30］Xu J X, Song J J, Chen X X, et al. Genomic instability-related twelve-microRNA signatures for predicting the prognosis of gastric cancer［J］. Comput Biol Med, 2023, 155: 106598.
［31］Reinert T, Schøler L V, Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery［J］. Gut, 2016, 65(4): 625-634.
［32］Li J, Li Z Y, Ding Y J, et al. TP53 mutation and met amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer［J］. PeerJ, 2021, 9: e11146.
［33］Lecomte T, Berger A, Zinzindohoué F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis［J］. Int J Cancer，2002 100(5):542-548.
［34］Peng Y, Mei W X, Ma K D, et al. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives［J］. Front Oncol, 2021, 11: 763790.
［35］Hasenleithner S O, Speicher M R. A clinician's handbook for using ctDNA throughout the patient journey［J］. Mol Cancer, 2022, 21(1): 81.
［36］Mathios D, Johansen J S, Cristiano S, et al. Detection and characterization of lungcancer using cell-free DNA fragmentomes［J］. Nat Commun, 2021, 12(1): 5060.

[1]	乔新伟, 邱煜婷, 李鹏, 吴静, 张澍田. 内镜下十二指肠乳头切除术后短期不良事件危险因素的初步探索[J]. 首都医科大学学报, 2023, 44(6): 982-989.
[2]	何振, 秦达, 李鹏, 朱圣韬, 冀明, 张澍田. 8字环辅助结直肠困难内镜下黏膜剥离术的临床效果评价[J]. 首都医科大学学报, 2023, 44(6): 973-977.
[3]	刘娟, 王文静, 赵桂平, 王拥军, 李鹏, 吴咏冬, 张澍田. 贲门失弛缓症经口内镜下肌切开术后复发危险因素分析[J]. 首都医科大学学报, 2023, 44(6): 978-981.
[4]	乔新伟, 邱煜婷, 李鹏, 吴静, 张澍田. 十二指肠乳头肿瘤患者的临床特征分析及其对肿瘤进展期的诊断价值[J]. 首都医科大学学报, 2023, 44(6): 990-998.
[5]	乔新伟, 邱煜婷, 李鹏, 吴静, 张澍田. 内镜下十二指肠乳头切除术后短期不良事件危险因素的初步探索[J]. 首都医科大学学报, 0, (): 982-989.
[6]	王亚丹, 王苗苗, 郭春梅, 台卫平, 刘红, 宿慧, 王沧海, 吴静. 急性胰腺炎严重程度早期预测模型的构建与验证[J]. 首都医科大学学报, 2023, 44(2): 302-310.
[7]	池添雨, 赵曲川. 胃黄色瘤合并肠上皮化生的临床分析[J]. 首都医科大学学报, 2023, 44(2): 322-327.
[8]	王芸, 李文坤, 苏珈仪, 王亚丹, 吴静. 系统免疫炎症指数在早期结直肠癌及癌前病变筛查中的应用价值[J]. 首都医科大学学报, 2022, 43(5): 760-766.
[9]	刘春涛, 苏珈仪, 旦增卓嘎, 伊比然恨, 卓玛, 张澍田. 西藏自治区藏族人群幽门螺杆菌毒力菌株分型与慢性胃炎及消化性溃疡的相关性研究[J]. 首都医科大学学报, 2022, 43(3): 463-468.
[10]	马鸣扬, 王洁玮, 李鹏. 细胞内镜评估结直肠病变的研究进展[J]. 首都医科大学学报, 2022, 43(2): 221-226.
[11]	苏珈仪, 刘春涛, 王铁山, 李文坤, 杨奕, 武珊珊, 李鹏, 吴静. 血清幽门螺杆菌抗体分型检测与胃黏膜病变的相关性[J]. 首都医科大学学报, 2022, 43(2): 216-220.
[12]	王荣欣, 王晶, 胡水清. 伴有食管外症状的反流性食管炎患者的危险因素分析[J]. 首都医科大学学报, 2022, 43(1): 132-137.
[13]	程芮, 朱思莹, 刘思茂, 周艳华, 宗晔, 李鹏, 张澍田. 内镜下治疗食管胃底静脉曲张伴发上消化道肿物的经验[J]. 首都医科大学学报, 2022, 43(1): 22-27.
[14]	李婕琳, 刘天宇, 张澍田, 隗永秋, 冀明, 李鹏, 王拥军, 吴咏冬. 十二指肠副乳头插管置入胰管支架的安全性评价[J]. 首都医科大学学报, 2022, 43(1): 28-33.
[15]	张兴华, 邢洁, 孙灿, 张希, 王拥军. 溃疡性结肠炎中B细胞对巨噬细胞趋化作用的初步研究[J]. 首都医科大学学报, 2022, 43(1): 42-46.